Utility of circulating tumor DNA in secondary liver malignancies: What we know and what is to come

IF 1.9 3区医学 Q3 ONCOLOGY Journal of Surgical Oncology Pub Date : 2024-08-19 DOI:10.1002/jso.27838

Chase J. Wehrle MD, Noah X. Tocci MD, Keyue Sun MD, Chunbao Jiao MD, Hanna Hong BS, Abby Gross MD, Erlind Allkushi BS, Melis Uysal MD, Maureen Whitsett Linganna MD, Katheryn Stackhouse MD, Koji Hashimoto MD, PhD, Andrea Schlegel MD, MBA, R. Matthew Walsh MD, Charles Miller MD, David C. H. Kwon MD, PhD, Federico Aucejo MD

{"title":"Utility of circulating tumor DNA in secondary liver malignancies: What we know and what is to come","authors":"Chase J. Wehrle MD, Noah X. Tocci MD, Keyue Sun MD, Chunbao Jiao MD, Hanna Hong BS, Abby Gross MD, Erlind Allkushi BS, Melis Uysal MD, Maureen Whitsett Linganna MD, Katheryn Stackhouse MD, Koji Hashimoto MD, PhD, Andrea Schlegel MD, MBA, R. Matthew Walsh MD, Charles Miller MD, David C. H. Kwon MD, PhD, Federico Aucejo MD","doi":"10.1002/jso.27838","DOIUrl":null,"url":null,"abstract":"<p>Secondary liver malignancies are a serious and challenging global health concern. Secondary metastasis to the liver is most commonly from colorectal cancer that has metastatically spread through splanchnic circulation. Metastatic diseases can portend poor prognosis due to the progressive nature typically found on detection. Improvements in detection of disease, monitoring therapy response, and monitoring for recurrence are crucial to the improvement in the management of secondary liver malignancies. Assessment of ctDNA in these patient populations poses an opportunity to impact the management of secondary liver malignancies. In this review, we aim to discuss ctDNA, the current literature, and future directions of this technology within secondary liver malignancies.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"131 5","pages":"888-894"},"PeriodicalIF":1.9000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jso.27838","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jso.27838","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Secondary liver malignancies are a serious and challenging global health concern. Secondary metastasis to the liver is most commonly from colorectal cancer that has metastatically spread through splanchnic circulation. Metastatic diseases can portend poor prognosis due to the progressive nature typically found on detection. Improvements in detection of disease, monitoring therapy response, and monitoring for recurrence are crucial to the improvement in the management of secondary liver malignancies. Assessment of ctDNA in these patient populations poses an opportunity to impact the management of secondary liver malignancies. In this review, we aim to discuss ctDNA, the current literature, and future directions of this technology within secondary liver malignancies.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

循环肿瘤 DNA 在继发性肝脏恶性肿瘤中的应用：我们所知道的和将要知道的

继发性肝脏恶性肿瘤是一个严重而具有挑战性的全球健康问题。继发性肝转移最常见于通过脾循环转移的结直肠癌。由于转移性疾病在发现时通常具有进展性，因此预后较差。改进疾病检测、治疗反应监测和复发监测对于改善继发性肝脏恶性肿瘤的治疗至关重要。在这些患者群体中评估ctDNA是影响继发性肝恶性肿瘤治疗的一个机会。在这篇综述中，我们旨在讨论ctDNA、当前文献以及这项技术在继发性肝恶性肿瘤中的未来发展方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Surgical Oncology 医学-外科

CiteScore

4.70

自引率

4.00%

发文量

367

审稿时长

2 months

期刊介绍： The Journal of Surgical Oncology offers peer-reviewed, original papers in the field of surgical oncology and broadly related surgical sciences, including reports on experimental and laboratory studies. As an international journal, the editors encourage participation from leading surgeons around the world. The JSO is the representative journal for the World Federation of Surgical Oncology Societies. Publishing 16 issues in 2 volumes each year, the journal accepts Research Articles, in-depth Reviews of timely interest, Letters to the Editor, and invited Editorials. Guest Editors from the JSO Editorial Board oversee multiple special Seminars issues each year. These Seminars include multifaceted Reviews on a particular topic or current issue in surgical oncology, which are invited from experts in the field.